Compare Johnson & Johnson (JNJ) vs State Street PDR S&P Retail ETF (XRT) Price & Performance

Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.

The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.

XRT trades at $88.94, down 0.54% today, with a bullish technical outlook from moving averages but neutral oscillators. Recent retail sales data shows five consecutive months of growth, supporting the ETF's consumer discretionary exposure. The fund offers diversified retail sector access but lacks specific valuation metrics in current data.

The ETF benefits from sustained consumer spending trends but faces headwinds from inflation and weak sentiment. Technical strength suggests near-term upside potential, though overbought RSI signals caution. Risks include macroeconomic pressures and sector volatility.